Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CMO David Shapiro sold 4,774 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $291.49, for a total transaction of $1,391,573.26. Following the transaction, the chief marketing officer now directly owns 14,253 shares of the company’s stock, valued at approximately $4,154,607. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on ICPT. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday. They now have a $456.00 price target on the stock, up previously from $323.00. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Intercept Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $472.91.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 3.93% during mid-day trading on Friday, hitting $284.70. 586,794 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 1-year low of $42.41 and a 1-year high of $497.00. The stock’s 50-day moving average is $234.8 and its 200-day moving average is $291.9. The company’s market cap is $6.040 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.50 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.